Ideas

Molecular therapy for Myocardial Infarction: Simvastatin (brand name: Zocor), a lipid-lowering medication, inhibits DNA damage responses, increases telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up-regulation of PNUTS, 8/January/2017, 11.26 pm
Molecular therapy for Myocardial Infarction: Simvastatin (brand name: Zocor), a lipid-lowering medication, inhibits DNA damage responses, increases telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up-regulation of PNUTS, 8/January/2017, 11.26 pm 150 150 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others. What we…

read more

Small molecule-based PD-1 pathway blockade for Human cancer therapy: Lovastatin (brand name: Mevacor), a hypolipidemic agent, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 8/January/2017, 10.46 pm
Small molecule-based PD-1 pathway blockade for Human cancer therapy: Lovastatin (brand name: Mevacor), a hypolipidemic agent, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 8/January/2017, 10.46 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say:  A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase…

read more

Molecular therapy for triple-negative breast tumors: Lovastatin (brand name: Mevacor), a statin drug used in the treatment of hypercholesterolemia, increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 8/January/2017, 9.54 pm
Molecular therapy for triple-negative breast tumors: Lovastatin (brand name: Mevacor), a statin drug used in the treatment of hypercholesterolemia, increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 8/January/2017, 9.54 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA shows that “PIM1 kinase inhibition as…

read more

Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: CGI-58(Comparative gene identification-58)/ABHD5 (α/β-hydrolase domain-containing 5) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 7/January/2017, 11.57 pm
Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: CGI-58(Comparative gene identification-58)/ABHD5 (α/β-hydrolase domain-containing 5) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 7/January/2017, 11.57 pm 150 150 Dr Boomi's Genom-2-Discovery Center

From Research findings to Therapeutic opportunity:  The study presented here suggests that CGI-58/ABHD5, by increasing the expression of its target genes, it may: (i) decrease the expression of Dihydropyrimidine dehydrogenase (DPYD); (ii) increase 5-FU accumulation…

read more

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Emodin (6-methyl-1,3,8-trihydroxy anthraquinone), found in Polygonum multiflorum, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 7/January/2017, 11.51 pm
Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Emodin (6-methyl-1,3,8-trihydroxy anthraquinone), found in Polygonum multiflorum, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 7/January/2017, 11.51 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA shows…

read more

Life-extension therapy: EF24, a curcumin analog, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 7/January/2017, 11.31 pm
Life-extension therapy: EF24, a curcumin analog, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 7/January/2017, 11.31 pm 150 150 Dr Boomi's Genom-2-Discovery Center

What they say? A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1…

read more
Start Typing